| 1 Global state: 1. Average endpoint score of CGI scales (high = poor) |
1 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 1.1 short term (up to 12 weeks) |
1 |
36 |
Mean Difference (IV, Random, 95% CI) |
‐0.34 [‐0.90, 0.22] |
| 2 Mental state: 2a. Average endpoint score of various scales (high = poor) |
2 |
|
Mean Difference (IV, Random, 95% CI) |
Subtotals only |
| 2.1 BPRS ‐ anxiety/depression subscale score ‐ short term (up to 12 weeks) |
1 |
57 |
Mean Difference (IV, Random, 95% CI) |
2.60 [1.40, 3.80] |
| 2.2 BPRS total score ‐ short term (up to 12 weeks) |
1 |
57 |
Mean Difference (IV, Random, 95% CI) |
5.10 [‐2.35, 12.55] |
| 2.3 SANS total score ‐ short term (up to 12 weeks) |
1 |
36 |
Mean Difference (IV, Random, 95% CI) |
‐9.49 [‐17.88, ‐1.10] |
| 3 Mental state: 2b. Average endpoint score of AMDP scale (high = poor) |
|
|
Other data |
No numeric data |
| 3.1 short term (up to 12 weeks) |
|
|
Other data |
No numeric data |
| 4 Adverse effects: 1. Extrapyramidal effects |
1 |
|
Risk Ratio (M‐H, Random, 95% CI) |
Subtotals only |
| 4.1 concomitant anticholinergic medication ‐ short term (up to 12 weeks) |
1 |
36 |
Risk Ratio (M‐H, Random, 95% CI) |
7.82 [1.07, 57.26] |
| 5 Leaving the study early |
2 |
|
Risk Ratio (IV, Random, 95% CI) |
Subtotals only |
| 5.1 any reason |
2 |
98 |
Risk Ratio (IV, Random, 95% CI) |
1.19 [0.63, 2.28] |
| 5.2 adverse effects ‐ short term (up to 12 weeks) |
2 |
98 |
Risk Ratio (IV, Random, 95% CI) |
1.88 [0.24, 14.68] |
| 5.3 inefficacy ‐ short term (up to 12 weeks) |
2 |
98 |
Risk Ratio (IV, Random, 95% CI) |
1.82 [0.68, 4.84] |
| 5.4 productive symptoms ‐ short term (up to 12 weeks) |
1 |
36 |
Risk Ratio (IV, Random, 95% CI) |
0.37 [0.04, 3.25] |
